Clarity Pharmaceuticals
- Company typePublic
- Founded2010
- HeadquartersSydney, Australia
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Clarity Pharmaceuticals firmographics
Firmographics- Name
- Clarity Pharmaceuticals
- Legal name
- Clarity Pharmaceuticals
- Website
- https://claritypharmaceuticals.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Clarity Pharmaceuticals industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
- akta.pro secondary industries
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Clarity Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices4 records
Markets served
Clarity Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Radiopharmaceutical Product Sales (Anticipated): Clarity is a clinical-stage company with no current product revenue. Upon successful completion of Phase III trials (AMPLIFY, CLARIFY) and FDA NDA approval, Clarity plans to commercialise 64Cu-SAR-bisPSMA as a next-generation PSMA PET diagnostic imaging agent for prostate cancer, and subsequently 67Cu-SAR-bisPSMA as a therapeutic agent. Revenue will be generated from product sales to hospitals, imaging centres, and nuclear medicine departments. The company has established large-scale manufacturing supply agreements with Theragenics, Nucleus RadioPharma, Nusano, UQ AIBN, and SpectronRx to support commercial launch capacity of over 2 million doses per year.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Clarity Pharmaceuticals product offering
Product offeringCore offering
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation Targeted Copper Theranostics (TCT) based on its proprietary SAR (Sarcophagine) chelator platform. Its products pair copper-64 (for diagnostic PET imaging) and copper-67 (for therapy) with tumour-targeting molecules, including SAR-bisPSMA for prostate cancer, SARTATE for neuroendocrine tumours and neuroblastoma, and SAR-Bombesin for pan-cancer indications. Upon FDA approval, finished doses will be supplied directly to hospitals, imaging centres and nuclear medicine departments.
Product overview
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing a portfolio of Targeted Copper Theranostics (TCT) based on its proprietary SAR Technology platform. The platform uses copper isotopes—copper-64 for diagnostic imaging and copper-67 for therapy—in combination with targeting molecules. The core products include SAR-bisPSMA (for prostate cancer), SARTATE (for neuroendocrine tumors and neuroblastoma), and SAR-Bombesin (pan-cancer product). The lead product SAR-bisPSMA is in Phase III registrational trials for diagnostic imaging and Phase II for therapeutic use. Preclinical pipeline includes SAR-bisFAP (pan-cancer) and SAR-trastuzumab (breast cancer). The company operates multiple clinical trials across the US and Australia.
Differentiator
Problem solved
Functional benefit
Products and services
- SAR-bisPSMA Platform
Quantifiable outcome
- 64Cu-SAR-bisPSMA detected mean 1.26 lesions per patient vs 0.48 for 68Ga-PSMA-11 (p<0.0001) in the Co-PSMA head-to-head Phase II trial, with 63 total lesions detected vs 24.
- +5 more outcomes
Companies that use Clarity Pharmaceuticals
Customer profileNamed customers11 records
Segments1 record
Ideal customer profiles1 record
Clarity Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Clarity Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Nucleus RadioPharmacoreCommercial Manufacturing Agreement for Cu-64 SAR-bisPSMA production. Covers Nucleus RadioPharma's existing facility in Rochester, Minnesota (50,000 doses/year) and a planned facility in Spring House, Pennsylvania opening in 2028 (600,000 doses/year), enabling nationwide US distribution and expansion to select international markets including Europe. A key step in Clarity's manufacturing buildout ahead of anticipated commercial launch pending FDA NDA approval.
- TheragenicscoreLarge-scale Manufacturing Supply Agreement for copper-64 production at Theragenics' 134,000 sq ft facility with 14 cyclotrons near Atlanta, Georgia. Capacity of ~100Ci copper-64 per day per cyclotron translates to ~2,000 patient doses per day per cyclotron, with a 48-hour shelf life. The Atlanta facility is a major US transport hub. This agreement complements existing copper-64 supply with SpectronRx and Nusano, enhancing Clarity's broad network of high-volume copper-64 manufacturers in distinct US geographies.
- NusanocoreThree-year copper-67 supply agreement with Utah-based Nusano, a company building an isotope production facility in Utah. Copper-67 is the therapeutic isotope used in 67Cu-SAR-bisPSMA for prostate cancer therapy. Supply expected to start in mid-2026, supporting Clarity's Phase III trials and commercial launch. Nusano's new production methods aim to ensure a sustainable and scalable supply of copper-67.
- EirGenix, Inc.coreSupply Agreement for clinical-grade GMP trastuzumab biosimilar (EG12014) to support the development of 64/67Cu-SAR-trastuzumab for HER2-positive breast cancer. EirGenix's trastuzumab (marketed as EIRGASUN in Taiwan, partnered with Sandoz as Herwenda in Europe) secures clinical supply for Clarity's radioimmunotherapy (RIT) program. EirGenix's Chairman commented that RIT using copper-67 is a promising avenue for next-generation antibody therapies.
- University of MelbourneminorAcademic collaboration with the University of Melbourne on pioneering work combining trastuzumab antibody with Clarity's SAR chelator for copper-64/67 radiolabelling, resulting in the 64/67Cu-SAR-trastuzumab preclinical asset.
- The University of Queensland (UQ) / AIBNcoreCopper-64 supply agreement with UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN). The AIBN houses an on-site cyclotron and state-of-the-art radiochemistry facilities supplying copper-64 weekly to Australian clinical trial sites. Supports Phase III CLARIFY and AMPLIFY trials in Australia, the Co-PSMA IIT at St Vincent's Hospital Sydney, and the SECuRE theranostic trial. Also supports preclinical programs including SAR-bisFAP and SAR-trastuzumab.
- ARC Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR)minorClarity is an active participant in the Australian Research Council (ARC) Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR), a collaborative R&D initiative advancing radiopharmaceutical manufacturing in Australia.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Clarity Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Novartis (Pluvicto / Lutathera franchise): Novartis commercializes Pluvicto (Lu-177 PSMA-617) for mCRPC and Lutathera for NETs — the most direct approved competitors to Clarity's SAR-bisPSMA and SARTATE. Both target the same indications with radioligand therapy, and Novartis' commercial scale and physician relationships set the competitive benchmark.
- Bayer (Curium / PSMA-617 franchise): Bayer acquired PSMA-617 rights and operates in the PSMA radioligand space alongside its broader oncology franchise. Broad incumbent with deep capital and a radioligand therapy competing directly with Clarity's SAR-bisPSMA therapeutic program in mCRPC.
- Bracco Imaging: Bracco is a global diagnostic imaging company with a radiopharmaceutical portfolio (including Ga-68 PSMA agents through Blue Earth Diagnostics). Broad incumbent with established imaging distribution infrastructure and overlapping prostate cancer imaging products.
- Curium Pharma: Curium is one of the world's largest nuclear medicine companies, manufacturing and distributing diagnostic radiopharmaceuticals including SPECT and PET agents. Relevant as a manufacturing and distribution competitor for hospital/nuclear medicine supply, with established relationships that Clarity's commercial team will compete against.
- GE HealthCare: GE HealthCare has a major radiopharmaceutical and PET imaging franchise, including manufacturing capacity and emerging theranostic partnerships. Broad incumbent whose scale in nuclear medicine supply and imaging infrastructure represents both competitive pressure and potential partnership optionality.
Direct peers
- Telix Pharmaceuticals: Telix is the most directly comparable clinical/commercial radiopharmaceutical peer, with approved Illuccix (Ga-68 PSMA-11 PET) for prostate cancer imaging and a pipeline of PSMA-targeted therapies. Same target class, similar distribution model to hospitals/imaging centers, and overlapping indications make it Clarity's closest competitor for both share-of-voice and commercial share.
- Lantheus Holdings: Lantheus markets Pylarify (F-18 DCFPyL) for PSMA PET imaging and has a PSMA-targeted radioligand therapy (PNT2002) in development. Direct competitor in prostate cancer imaging with established US commercial infrastructure and similar radiopharmaceutical business model.
- POINT Biopharma: POINT Biopharma develops PSMA-targeted radioligand therapies (including PNT2002 in collaboration with Lantheus). Directly comparable as a clinical-stage radiopharmaceutical company targeting prostate cancer with Lu-177-based therapies.
- Fusion Pharmaceuticals: Fusion Pharmaceuticals is a clinical-stage radiopharmaceutical company developing targeted alpha therapies (actinium-225) across multiple tumor types. Comparable business model, technology platform approach, and oncology focus make it a relevant emerging peer.
Emerging players
- Actinium Pharmaceuticals: Actinium develops antibody-radionuclide conjugates for hematologic cancers using actinium-225. Comparable as a clinical-stage radiopharmaceutical company with platform technology, though focused on different isotopes and indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Clarity Pharmaceuticals social profiles
Digital presenceClarity Pharmaceuticals compliance and trust
Trust signalCompliance5 records
Clarity Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clarity Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles9 records
Clarity Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds7 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clarity Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clarity Pharmaceuticals
What does Clarity Pharmaceuticals do?
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation Targeted Copper Theranostics (TCT) based on its proprietary SAR (Sarcophagine) chelator platform. Its products pair copper-64 (for diagnostic PET imaging) and copper-67 (for therapy) with tumour-targeting molecules, including SAR-bisPSMA for prostate cancer, SARTATE for neuroendocrine tumours and neuroblastoma, and SAR-Bombesin for pan-cancer indications. Upon FDA approval, finished doses will be supplied directly to hospitals, imaging centres and nuclear medicine departments.
Is Clarity Pharmaceuticals a public or private company?
Clarity Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Clarity Pharmaceuticals founded?
Clarity Pharmaceuticals was founded in 2010. It employs 51 to 100 people.
Where is Clarity Pharmaceuticals based?
Clarity Pharmaceuticals is headquartered in Sydney, Australia, in the Oceania region.
How does Clarity Pharmaceuticals make money?
One revenue line is on record: radiopharmaceutical Product Sales (Anticipated).
Who are Clarity Pharmaceuticals's main competitors?
Broad incumbents on record are Novartis (Pluvicto / Lutathera franchise), Bayer (Curium / PSMA-617 franchise), Bracco Imaging, Curium Pharma and GE HealthCare. Direct peers are Telix Pharmaceuticals, Lantheus Holdings, POINT Biopharma and Fusion Pharmaceuticals. Actinium Pharmaceuticals is listed as an emerging player.
Does Clarity Pharmaceuticals have an API?
No public API is recorded for Clarity Pharmaceuticals.
What industry is Clarity Pharmaceuticals in?
Clarity Pharmaceuticals's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325412 and its SIC code is 2834.